Inquiry Basket
CAS No.: 400647-59-8
Cat No.: BADC-01122
Purity: >99.3%
4.5 
Doxorubicin-SMCC is a pre-activated ADC linker-payload combining a cytotoxic agent with a maleimide NHS ester linker. Enables targeted drug delivery by conjugating with antibody thiol groups.
Structure of 400647-59-8
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Doxorubicin-SMCC, a pivotal conjugate utilized in targeted cancer therapies and biomedical research, showcases a multitude of applications. Here are four key applications of Doxorubicin-SMCC:
Targeted Cancer Therapy: Pioneering the landscape of targeted cancer therapy, Doxorubicin-SMCC assumes a pivotal role in crafting antibody-drug conjugates (ADCs) tailored to selectively target cancer cells while preserving the integrity of healthy tissues. By conjugating Doxorubicin-SMCC with antibodies recognizing tumor-specific antigens, the drug is precisely delivered to malignant cells, ushering in a paradigm shift in treatment precision and mitigating systemic toxicity, ushering in a sophisticated approach to cancer therapy.
Drug Delivery System Research: Positioned at the forefront of drug delivery system exploration, Doxorubicin-SMCC serves as a cornerstone for delving into and refining drug delivery mechanisms. Researchers delve into the intricate dynamics of stability, release kinetics, and biodistribution of this versatile conjugate across diverse formulations. Revelations derived from unraveling these complexities have the potential to drive the evolution of advanced targeted drug delivery platforms, potentially enhancing treatment outcomes across a spectrum of medical conditions.
Bioconjugation Studies: In the realm of bioconjugation research, Doxorubicin-SMCC emerges as a catalytic agent for dissecting the chemical bonds between drugs and targeting molecules. By harnessing the SMCC linker, researchers securely anchor Doxorubicin to proteins or peptides, paving the way for innovative conjugation strategies. Discoveries stemming from these intricate studies hold the promise of catalyzing the development of novel therapeutics and diagnostic tools.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00892 | N-(Iodoacetamido)-Doxorubicin | 114390-30-6 | |
| 1547491-85-9 | N-([1,1'-biphenyl]-4-yl)-[1,1':3',1''-terphenyl]-4'-amine | 1547491-85-9 | |
| BADC-00042 | Daunorubicin | 20830-81-3 | |
| BADC-00039 | Doxorubicin | 23214-92-8 | |
| BADC-00038 | Doxorubicin hydrochloride | 25316-40-9 | |
| BADC-00363 | Aldoxorubicin hydrochloride | 480998-12-7 | |
| BADC-01412 | MA-PEG4-VC-PAB-DMAE-Doxorubicin | ||
| BADC-01462 | N3-PEG4-DYKDDDD-Doxorubicin | ||
| BADC-01463 | Azide-PEG4-VC-PAB-Doxorubicin | ||
| BADC-01464 | N3-PEG4-YPYDVPDYA-Doxorubicin |
Doxorubicin-SMCC
Required fields are marked with *
Doxorubicin-SMCC
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
